FI4009978T3 - Sepiapteriiinin ja sen metaboliittien käyttö säteilyaltistuksen hoitoon - Google Patents

Sepiapteriiinin ja sen metaboliittien käyttö säteilyaltistuksen hoitoon Download PDF

Info

Publication number
FI4009978T3
FI4009978T3 FIEP20758407.9T FI20758407T FI4009978T3 FI 4009978 T3 FI4009978 T3 FI 4009978T3 FI 20758407 T FI20758407 T FI 20758407T FI 4009978 T3 FI4009978 T3 FI 4009978T3
Authority
FI
Finland
Prior art keywords
sepiapterin
mir
pharmaceutically acceptable
mixed crystal
acceptable salt
Prior art date
Application number
FIEP20758407.9T
Other languages
English (en)
Finnish (fi)
Inventor
Eleonora Mezzaroma
Christopher Rabender
Ross Mikkelsen
Vasily Yakovlev
Neil Smith
Original Assignee
Ptc Therapeutics Mp Inc
Univ Virginia Commonwealth
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ptc Therapeutics Mp Inc, Univ Virginia Commonwealth filed Critical Ptc Therapeutics Mp Inc
Application granted granted Critical
Publication of FI4009978T3 publication Critical patent/FI4009978T3/fi

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
FIEP20758407.9T 2019-08-05 2020-08-05 Sepiapteriiinin ja sen metaboliittien käyttö säteilyaltistuksen hoitoon FI4009978T3 (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962882937P 2019-08-05 2019-08-05
PCT/US2020/045026 WO2021026247A1 (en) 2019-08-05 2020-08-05 Use of sepiapterin and metabolites thereof to treat radiation exposure

Publications (1)

Publication Number Publication Date
FI4009978T3 true FI4009978T3 (fi) 2024-11-01

Family

ID=72148243

Family Applications (1)

Application Number Title Priority Date Filing Date
FIEP20758407.9T FI4009978T3 (fi) 2019-08-05 2020-08-05 Sepiapteriiinin ja sen metaboliittien käyttö säteilyaltistuksen hoitoon

Country Status (21)

Country Link
US (1) US20220273661A1 (https=)
EP (2) EP4454712A3 (https=)
JP (2) JP7642611B2 (https=)
CN (2) CN114555090B (https=)
AU (1) AU2020324435B2 (https=)
BR (1) BR112022002029A2 (https=)
CA (1) CA3146477A1 (https=)
DK (1) DK4009978T3 (https=)
ES (1) ES2994060T3 (https=)
FI (1) FI4009978T3 (https=)
HR (1) HRP20241653T1 (https=)
HU (1) HUE069012T2 (https=)
IL (1) IL290321B1 (https=)
LT (1) LT4009978T (https=)
MX (1) MX2022001535A (https=)
PL (1) PL4009978T3 (https=)
PT (1) PT4009978T (https=)
RS (1) RS66096B1 (https=)
SI (1) SI4009978T1 (https=)
SM (1) SMT202500089T1 (https=)
WO (1) WO2021026247A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA46973A (fr) 2016-11-29 2019-10-09 Censa Pharmaceuticals Inc Polymorphes de sépiaptérine et leurs sels
MA46972A (fr) 2016-11-29 2019-10-09 Censa Pharmaceuticals Inc Forme polymorphe de sépiaptérine
JP7811085B2 (ja) 2017-09-01 2026-02-04 ピーティーシー セラピューティクス エムピー,インコーポレイテッド セピアプテリンを含む医薬組成物及びその使用
FI3801536T3 (fi) 2018-05-30 2024-08-29 Ptc Therapeutics Mp Inc Sepiapteriinin antaminen ilman ruokaa käytettäväksi menetelmässä sepiapteriinin plasma-altistuksen lisäämiseksi
EP3801534B1 (en) 2018-05-30 2026-02-18 PTC Therapeutics MP, Inc. Treatment of phenylketonuria with sepiapterin
IL290321B1 (en) * 2019-08-05 2026-04-01 Ptc Therapeutics Inc Use of spiapterin and its metabolites for radiation exposure treatment

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5910304A (en) 1982-12-13 1999-06-08 Texas A&M University System Low-dose oral administration of interferons
CA1320905C (en) 1986-11-06 1993-08-03 Joseph M. Cummins Treatment of immuno-resistant disease
US6036949A (en) 1998-03-05 2000-03-14 Amarillo Biosciences, Inc. Treatment of fibromyalgia with low doses of interferon
WO2005048926A2 (en) 2003-11-13 2005-06-02 The General Hospital Corporation Methods for treating pain
KR20070084270A (ko) 2004-11-17 2007-08-24 바이오마린 파머수티컬 인크. 안정한 정제 제형물
TWI359019B (en) * 2006-08-14 2012-03-01 Merck Eprova Ag Use of folates for the prevention and treatment of
MX379061B (es) 2013-09-13 2025-03-04 Bioventures Llc Preparacion y uso de una composicion para la prevencion y mitigacion de los efectos de la radiacion.
CN106794197A (zh) 2014-10-02 2017-05-31 西托索尔本茨公司 经胃肠施用的多孔消化道吸着剂聚合物用于预防或治疗辐射诱导的黏膜炎、食管炎、小肠炎、结肠炎和胃肠急性放射综合征的用途
MA46973A (fr) 2016-11-29 2019-10-09 Censa Pharmaceuticals Inc Polymorphes de sépiaptérine et leurs sels
MA46972A (fr) 2016-11-29 2019-10-09 Censa Pharmaceuticals Inc Forme polymorphe de sépiaptérine
JP7811085B2 (ja) 2017-09-01 2026-02-04 ピーティーシー セラピューティクス エムピー,インコーポレイテッド セピアプテリンを含む医薬組成物及びその使用
AU2019277372B2 (en) 2018-05-30 2024-12-19 Ptc Therapeutics Mp, Inc. Pharmaceutically acceptable salts of sepiapterin
IL290321B1 (en) * 2019-08-05 2026-04-01 Ptc Therapeutics Inc Use of spiapterin and its metabolites for radiation exposure treatment
CN110354133A (zh) * 2019-08-26 2019-10-22 鞍山市肿瘤医院 四氢生物蝶呤的应用及药物

Also Published As

Publication number Publication date
CN114555090A (zh) 2022-05-27
US20220273661A1 (en) 2022-09-01
EP4454712A3 (en) 2025-01-01
JP2025098011A (ja) 2025-07-01
EP4009978A1 (en) 2022-06-15
HUE069012T2 (hu) 2025-02-28
EP4009978B1 (en) 2024-09-25
ES2994060T3 (en) 2025-01-16
CN119837879A (zh) 2025-04-18
SI4009978T1 (sl) 2025-03-31
BR112022002029A2 (pt) 2022-06-07
CA3146477A1 (en) 2021-02-11
RS66096B1 (sr) 2024-11-29
AU2020324435A1 (en) 2022-02-24
JP2022543655A (ja) 2022-10-13
IL290321B1 (en) 2026-04-01
LT4009978T (lt) 2024-11-25
HRP20241653T1 (hr) 2025-04-25
PL4009978T3 (pl) 2025-02-24
PT4009978T (pt) 2024-11-05
WO2021026247A1 (en) 2021-02-11
IL290321A (en) 2022-04-01
CN114555090B (zh) 2024-12-17
JP7642611B2 (ja) 2025-03-10
MX2022001535A (es) 2022-03-04
AU2020324435B2 (en) 2026-03-19
DK4009978T3 (da) 2024-10-14
SMT202500089T1 (it) 2025-03-12
EP4454712A2 (en) 2024-10-30

Similar Documents

Publication Publication Date Title
FI4009978T3 (fi) Sepiapteriiinin ja sen metaboliittien käyttö säteilyaltistuksen hoitoon
ES2218638T3 (es) Uso de inhibidores de la histona-descarboxilasa para tratar la fibrosis.
JP2022543655A5 (https=)
Tao et al. Inhibition of Th1/Th17 responses via suppression of STAT1 and STAT3 activation contributes to the amelioration of murine experimental colitis by a natural flavonoid glucoside icariin
Brücken et al. Dose dependent neuroprotection of the noble gas argon after cardiac arrest in rats is not mediated by KATP—channel opening
EA200800161A1 (ru) Новые фармацевтические композиции с модифицированным высвобождением и способ получения таких композиций
Wu et al. Protective effects of aloperin on monocroline-induced pulmonary hypertension via regulation of Rho A/Rho kinsase pathway in rats
RU2008152341A (ru) Применение аллопуринола для лечения ладонно-подошвенной эритродизестезии
PH12021553102A1 (en) Methods of treating fabry disease in patients having renal impairment
CL2023000296A1 (es) Uso de dexpramipexol para el tratamiento del asma moderado a grave
JP2018503685A5 (https=)
FI3989962T3 (fi) Asetyylileusiinia ja miglustaattia sisältävä yhdistelmähoito lysosomaalisen kertymäsairauden hoidossa
RU2016103098A (ru) Способ предотвращения и/или лечения хронической травматической энцефалопатии - ii
CN107441071A (zh) 一种芳姜黄酮在制备治疗和/或预防银屑病药物中的应用
Wang et al. Tissue injury by hot fluid containing nitrogen mustard
FI3261625T3 (fi) Kolmena pulssina vapauttavia stimulanttiformulaatioita
Touma et al. A case of pheochromocytoma presenting with cardiopulmonary arrest
WO2011053700A1 (en) Methods to mitigate injury from radiation exposure
WO2024173520A3 (en) Rnai agents for inhibiting expression of thymic stromal lymphopoietin (tslp), compositions thereof, and methods of use
Vadivelan et al. The ‘golden hour’in paraquat poisoning
CN118831115B (zh) 用于治疗和/或预防脓毒症的中药组合物、药物制剂及用途
CN106727504B (zh) 辛伐他汀在制备预防高分压氧导致的肺型氧中毒的药物中的应用
WO2020264201A8 (en) Lemborexant for treating sleep issues
Chen et al. Role of sodium-hydrogen exchanger-1 (NHE-1) in the effect of exercise on intermittent hypoxia-induced left ventricular dysfunction
RU2538433C1 (ru) Фармацевтическая композиция для профилактики и лечения инфекционно-воспалительных заболеваний различной этиологии путем оромукозного введения